

MRI to assess arrhythmic risk post-MI

Jeffrey Goldberger, MD
**Director, Cardiac Electrophysiology
Research**
Professor of Medicine

Disclosures

- u **Research/Lectures - Boston Scientific, Medtronic.
St. Jude**

SCD Epidemiology

- u **Sources of information**
- u **Range 184,000 – 462,000**
- u **Etiologies of SCD**
 - **Ventricular tachyarrhythmias – VT/VF**
 - **Bradyarrhythmias**
 - **Nonarrhythmic causes – aneurysm, PE, myocardial rupture**

Variables Associated with Increased Risk for SCD

- u Low EF**
- u VEA**
- u HRV, BRS, HR, HRR, HRT**
- u Repolarization abnormalities - QT interval, QT dispersion, T wave alternans**
- u Depolarization abnormalities - SAECG, QRS duration**
- u Functional class**

AHA/ACC/HRS Scientific Statement

American Heart Association/American College of Cardiology/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death

**A Scientific Statement From the American Heart Association Clinical
Cardiology Council Committee on Electrocardiography and Arrhythmias
and the Epidemiology and Prevention Council**

Jeffrey J. Goldberger, MD, FAHA, FACC, FHRS; Michael E. Cain, MD, FAHA, FACC, FHRS;
Stefan H. Hohnloser, MD, FACC; Alan H. Kadish, MD, FAHA, FACC;
Bradley P. Knight, MD, FACC; Michael S. Lauer, MD, FAHA, FACC;
Barry J. Maron, MD, FACC; Richard L. Page, MD, FAHA, FACC, FHRS;
Rod Passman, MD, MSCE, FACC; David Siscovick, MD, MPH, FAHA;
William G. Stevenson, MD, FAHA, FACC, FHRS; Douglas P. Zipes, MD, FAHA, MACC, FHRS

Table. Summary of Noninvasive Risk-Stratification Techniques for Identifying Patients With Coronary Artery Disease Who Are at Risk for Sudden Cardiac Death (SCD)

Technique	Conclusion
1. LVEF	Although low LVEF has been effectively used to select high-risk patients for application of therapy to prevent sudden arrhythmic death, LVEF has limited sensitivity: the majority of SCDs occur in patients with more preserved LVEF.
2. ECG and Holter <ul style="list-style-type: none">•Ectopy and NSVT•Signal averaged ECG•QRS duration•Heart rate variability•QT dynamics	
3. Exercise test/functional status <ul style="list-style-type: none">•NYHA class•Heart rate recovery•T-wave alternans	In some populations, the presence of NSVT has been effectively used to select high-risk patients for application of therapy to prevent sudden arrhythmic death. This may also have limited sensitivity.

Table. Summary of Noninvasive Risk-Stratification Techniques for Identifying Patients With Coronary Artery Disease Who Are at Risk for Sudden Cardiac Death (SCD)

Technique	Conclusion
<ol style="list-style-type: none">1. LVEF2. ECG and Holter<ul style="list-style-type: none">• Ectopy and NSVT• Signal averaged ECG• QRS duration• Heart rate variability• QT dynamics3. Exercise test/functional status<ul style="list-style-type: none">• NYHA class• Heart rate recovery• T-wave alternans	<p>Clinical utility to guide selection of therapy has not yet been tested.</p>

Table. Summary of Noninvasive Risk-Stratification Techniques for Identifying Patients With Coronary Artery Disease Who Are at Risk for Sudden Cardiac Death (SCD)

Technique	Conclusion
<ol style="list-style-type: none">1. LVEF2. ECG and Holter<ul style="list-style-type: none">•Ectopy and NSVT•Signal averaged ECG•QRS duration•Heart rate variability•QT dynamics3. Exercise test/functional status<ul style="list-style-type: none">•NYHA class•Heart rate recovery•T-wave alternans	Clinical utility to guide selection of therapy has been tested, but not yet demonstrated.

Circulation. 2008;118:1497-1518.

GUSTO 2-YEAR SURVIVAL

EF > 40%

N=1701

2 year mortality 6.8%

Total # of deaths 116

EF > 40% n = 1701


EF ≤ 40%

N=242

2 year mortality 25.2%

Total # of deaths 61

EF ≤ 40% n = 242




EF > 40%	60	11	6	4	2	6	0	6	7	4	2	5	3
EF ≤ 40%	36	5	4	3	2	1	0	2	2	2	2	1	1
Cumulative Deaths per interval													

Oregon Sudden Unexpected Death Study


- u Multnomah County - 660,486; 2002-4
- u 714 SCD - 54/100,000
- u Pre-SCD EF in 121 (17%)
 - Normal - 48%
 - 36-54% - 22%
 - $\leq 35\%$ - 30%

Sudden Cardiac Deaths – Incidence and Total Events




Canine Model


Extent of myocardial scar is related to inducibility of VT




Sustained Monomorphic VT: Reentry in an infarct scar




Channel / Isthmus





Sustained Monomorphic VT: Reentry in an infarct scar






Channel / Isthmus














Diastole


Systole

Contrast


Contours



Base



Mid



Apex


Infarct Morphology Identifies Patients With Substrate for Sustained VT

u 48 pts with CAD undergoing EPS


- 21 not inducible EF $35 \pm 3\%$
- 18 MVT EF $28 \pm 2\%$
- 9 PVT/VF EF $34 \pm 6\%$

u MRI results



- | | | |
|-----------|-----------------------|------------------------------|
| - 21 NI: | Inf mass $14 \pm 3\%$ | SA $93 \pm 14 \text{ cm}^2$ |
| - 18 MVT: | Inf mass $26 \pm 3\%$ | SA $172 \pm 15 \text{ cm}^2$ |
| | <0.009 | <0.002 |




ROC Curves




64 y.o. male with IMI, LVEF 61%,
27% MDE_{periph}, died 11 mos post-MI





Prognostic Significance of DE MRI




STUDY ²	Population ²	N ²	LVEF ²	Outcome ²	Finding ²
Bello ²⁰⁰⁵⁽¹³⁾ ²	CAD referred for EPS ²	48 ²	32% ²	Inducible VT ²	Infarct size better predictor than LVEF ²
Kwong ²⁰⁰⁶⁽⁴⁾ ²	No known prior MI ²	195 ²	54% ²	Death, MI, CV hosp, ICD tx ²	LGE strongest predictor of CV events ²
Yan ²⁰⁰⁶⁽⁹⁾ ²	CAD with LGE on CMR ²	144 ²	44% ²	Mortality ²	Border zone independent predictor of mortality ²
Assomull ²⁰⁰⁶⁽¹⁴⁾ ²	DCM ²	101 ²	31% ²	Mortality ± CV hosp ²	LGE only independent predictor ²
Schmidt ²⁰⁰⁷⁽⁷⁾ ²	CAD, LVEF < 35%, referred for ICD ²	47 ²	27% ²	Inducible VT ²	Gray zone only predictive variable ²
Wu ²⁰⁰⁸⁽¹⁵⁾ ²	CAD & pSTEMI ²	128 ²	41% ²	Death, MI, CV hosp ²	Acute infarct size better predictor than LVEF ²
Yokata ²⁰⁰⁸⁽¹⁶⁾ ²	CAD, EF ≤ 50%, revasc ± ICD ²	86 ²	26% ²	Death, CV hosp, revasc, VA ²	Infarct size was best predictor, not LVEF ²
Wu ²⁰⁰⁸⁽¹⁷⁾ ²	DCM, LVEF ≤ 35% ²	65 ²	22% ²	Death, ICD tx, CV hosp ²	LGE only independent predictor ²
Cheong ²⁰⁰⁹⁽¹⁸⁾ ²	Any pt w/ CMR, no infiltrative dz ²	857 ²	39% ²	Transplant-free survival ²	Scar index and LVEF are independent predictors ²
Kelle ²⁰⁰⁹⁽¹⁹⁾ ²	CAD ²	177 ²	45% ²	Mortality ± nonfatal MI ²	Spatial scar extent better predictor than LVEF ²
Roes ²⁰⁰⁹⁽⁸⁾ ²	ICM, getting ICD ²	91 ²	28% ²	Appropriate ICD tx ²	Gray zone only predictive variable ²
Kwon ²⁰⁰⁹⁽²⁰⁾ ²	CAD, LVEF < 45% ²	349 ²	24% ²	Transplant-free survival ²	Infarct size was best predictor, not LVEF ²
Heidary ²⁰¹⁰⁽²¹⁾ ²	CAD, EF ≤ 50%, revasc ± ICD ²	70 ²	25% ²	Death, CV hosp, revasc, VA ²	Border zone and total scar are predictive, not LVEF ²
Bello ²⁰¹¹⁽²²⁾ ²	CAD ²	100 ²	34% ²	Mortality ²	Infarct size and LVEF are independent predictors ²
Perez-David ²⁰¹¹⁽¹⁰⁾ ²	CAD, ablation of monomorphic VT ²	36 ²	32% ²	VT ²	More heterogeneous tissue channels in VT ²
Scott ²⁰¹¹⁽²³⁾ ²	CAD, getting ICD ²	64 ²	30% ²	Appropriate ICD tx ²	Number of transmural segments most predictive ²
Iles ²⁰¹¹⁽²⁴⁾ ²	ICM and DCM getting ICD ²	103 ²	26% ²	ICD tx ²	LGE predictive of ICD tx ²
Catalano ²⁰¹²⁽²⁵⁾ ²	CAD ²	376 ²	51% ²	Mortality + new onset HF ²	Infarct size and LVEF are independent predictors ²
Klem ²⁰¹²⁽³⁾ ²	ICM and DCM getting EPS ± ICD ²	73 ²	30% ²	SCD or ICD discharge ²	Infarct size is an independent predictor ²
Gao ²⁰¹²⁽²⁶⁾ ²	ICM and DCM getting ICD ²	59 ²	26% ²	SCD or ICD discharge ²	Infarct size is an independent predictor ²
Wu ²⁰¹²⁽²⁷⁾ ²	+CAD (53%) and CAD, for EPS ± ICD ²	137 ²	26% ²	ICD tx / cardiac death ²	Gray zone predictive ²
Dawson ⁽²⁾ ²	Sustained or nonsustained VT ²	373 ²	60% ²	SCD, VT/VF, ICD tx ²	LGE only independent predictor ²


DETERMINE

- u **CAD**
- u **No current indication for ICD**
- u **Infarct size > 10%**
- u **Randomization to Optimal medical therapy or OMT + ICD**

Sustained Monomorphic VT: Reentry in an infarct scar



Channel / Isthmus



Noninvasive Identification of Ventricular Tachycardia-Related Conducting Channels Using Contrast-Enhanced Magnetic Resonance Imaging in Patients With Chronic Myocardial Infarction

Comparison of Signal Intensity Scar Mapping and Endocardial Voltage Mapping

Esther Perez-David, MD,* Ángel Arenal, MD,* José L. Rubio-Guivernau, PHD,†
Roberto del Castillo, MD,* Leonardo Atea, MD,* Elena Arbelo, MD, PHD,‡
Eduardo Caballero, MD, PHD,‡ Verónica Celorrio, MD,* Tomas Datino, MD, PHD,*
Esteban Gonzalez-Torrecilla, MD, PHD,* Felipe Atienza, MD,* Maria J. Ledesma-Carbayo, PHD,†
Javier Bermejo, MD,* Alfonso Medina, MD, PHD,‡ Francisco Fernández-Avilés, MD, PHD*
Madrid and Las Palmas de Gran Canaria, Spain

MR Signal Intensity Map




Table 3

Segment Location and Orientation of CC and SI Channels

Patient #	Infarct Location	Endocardial Voltage Mapping			Endocardial SI Mapping	
		Channel n° and Segment Location	Orientation	VT-Related	Channel n° and Segment Location	Orientation
1	Ant	1: 3, 2, 1	Per		1: 3, 2, 1	Per
2	Inf	1: 6, 8	Para	+	1: 6, 8	Para
		2: 3, 5, 7	Para		2: 3, 5, 7	Para
3	Inf	1: 5, 6	Per	+	1: 5, 6	Per
4	Inf	1: 4, 6, 8	Para	+	1: 4, 6, 8	Para
5	Inf-Lat	1: 6, 8	Para		1: 6, 8	Para
		2: 6, 8, 5, 7	Per	+	2: 6, 8, 5, 7	Per
6	Ant					
7	Inf	1: 6	Para		1: 6	Para
		2: 6, 5	Para	+	2: 6, 5	Para
		3: 4, 6	Per		3: 4, 6	Per
8	Inf	1: 4, 6	Per		1: 4, 6	Per
9	Inf	1: 6, 8	Para	+	1: 6, 8	Para
10	Inf	1: 5, 6	Para	+	1: 5, 6	Para
11	Inf	1: 6	Para	+	1: 6	Para
12	Inf-Lat	1: 6	1: Para	+	1: 6	1: Para
		2: 5, 7, 6, 8	2: Per		2: 5, 7, 6, 8	2: Per
13	Inf	1: 6	Para	+	1: 6	Para
14	Ant	1-2	Para	+	1-2	Para
15	Inf	1: 6, 8	Para	+	1: 6, 8	Para
		2: 5, 6	Para		2: 5, 6	Para
		3: 4, 6	Per		3: 4, 6	Per
16	Ant	1: 2, 3	Para	+	1: 2, 3	Para
		2: 2, 3, 4	Per		2: 2, 3, 4	Per
17	Inf-Lat	1: 6, 8	Para	+	1: 6, 8	Para
		2: 4, 6	Per		2: 4, 6	Per
18	Inf	1: 6	Para	+	1: 6	Para


Virtual Electrophysiological Study in a 3-Dimensional Cardiac Magnetic Resonance Imaging Model of Porcine Myocardial Infarction

Jason Ng, PHD,* Jason T. Jacobson, MD,* Justin K. Ng, MS,* David Gordon, MD, PHD,*
Daniel C. Lee, MD,* James C. Carr, MD,† Jeffrey J. Goldberger, MD*


Chicago, Illinois

Virtual Electrophysiologic Testing Using Cardiac MRI

- 3D ceMRI to reconstruct LV and define scar
- At sites of normal LV - normal conduction
- At sites of scar - no conduction
- At border zone - slowed conduction
- Model propagation




Selected Left Ventricle




Complete 3D Model of Left Ventricle

Building the 3D Computer Model



Mathematical Model of the Action Potential

- Fenton-Karma 3 Variable Model
- Approximates Na^+ , K^+ , and Ca^{2+} dynamics
- Fast computation
- Restitution properties easily adjusted



Propagation equation

$$\frac{\partial V}{\partial t} = \frac{-(I_{ion} + I_{stim})}{C_m} + D \left(\frac{\partial^2 V}{\partial x^2} + \frac{\partial^2 V}{\partial y^2} + \frac{\partial^2 V}{\partial z^2} \right)$$

V = transmembrane potential

I_{ion} = Net ion current

I_{stim} = Stimulus current

C_m = Membrane capacitance

D = diffusion constant

Fenton-Karma 3-variable action potential model


$$I_{ion} = J_{fi} + J_{so} + J_{si}$$

$$J_{fi}(u; v) = -\frac{v}{\tau_d} \Theta(u - u_c)(1 - u)(u - u_c), \quad (\text{Fast inward current})$$

$$J_{so}(u) = \frac{u}{\tau_o} \Theta(u_c - u) + \frac{1}{\tau_r} \Theta(u - u_c), \quad (\text{Slow outward current})$$

$$J_{si}(u; w) = -\frac{w}{2\tau_{si}} (1 + \tanh[k(u - u_c^{si})]). \quad (\text{Slow inward current})$$

Partial differential equations solved by Euler forward method



Infarct

Healthy Myocardium

Stimulation Site

Edit Previewer

1:20

Add Stimulation Point

Delete Stimulation Point

X: 21 Radius: 5

Y: 34 Enable Cell

Z: 1 Disable Cell

Stimulation Time: 2000

Cell Str: 1


Open Stimulation Properties




Save Stimulation Properties

Fenton-Karma Mitchell-Schaeffer

Optimize Cell Data


VT Induction Example







EnGuide: R = 25.3 [Z = -22.3]











Proximity to EnSite surface:
-4.5 mm








Simulation




Non-Contact Mapping



Simulation



Non-Contact Mapping




New Paradigm - Virtual Electrophysiologic Study (VEPS)


SCAN




DE-MRI IMAGES




3D LV MODEL



VT INDUCTION SIMULATION



**CLINICAL
DECISION
MAKING?**



VEPS in Human MRIs

- 3D MRIs were collected from 16 patients with prior MI and 16 controls with no MI

	MI Patients	Controls	
	(n=16)	(n=16)	P value
Age (years)	64±10	55±10	0.03
Male	12 (75%)	10 (62.5%)	0.7
LVEF (%)	41.6±11.6	62.6±8.0	<0.0001
LV mass (g)	149.3±40.0	103.0±32.1	0.0005
LV Infarct %	13.2±8.8	N/A	


VEPS in Human MRIs

Results

- Six of 16 MI patients were inducible with VEPS
- None of the controls were inducible

	MI VEPS+ (n=6)	MI VEPS- (n=10)	P value
Age (years)	68±9	60±9	0.47
Male	4 (66%)	8 (80%)	0.6
LVEF (%)	34±9	46±11	0.011
LV mass (g)	149.8±39.6	149.0±34.5	0.45
LV Infarct %	20.0±8.9%	9.1±6.0%	0.046

Patient 1



MRI to assess arrhythmic risk post-MI

- u MRI provides the best clinical method available to define infarct characteristics -
? substrate for VT**
- u Promising tool to improve upon LVEF as risk marker for arrhythmic SCD**
- u Enhanced imaging and data processing will make this more realistic**